Biocryst looks to raise the profile of its factor D inhibitor
The relatively low-key asset might at least partly be responsible for Biocryst shares more than doubling since the start of December.
Bluebird split looks premature
Today’s safety scare with Lentiglobin calls into question the logic behind Bluebird’s planned business separation.
Agios strengthens the case for mitapivat
A filing in pyruvate kinase deficiency beckons, but bigger indications could be trickier.
Apellis takes the complement fight to Astrazeneca
The smaller company believes that its complement C3 inhibitor could make Soliris and Ultomiris redundant in PNH.
Pivotal valrox data give Biomarin déjà vu
Waning factor VIII levels mean the durability question is still unanswered.
Agios gets $1.8bn and a new focus
Selling its cancer drugs to Servier leaves Agios more reliant on mitapivat.
Ash 2020 movers – shorts roasting on an open fire
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
